Clinical Trial

Evaluate the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of BGM0504 Tablets in Non-diabetic Overweight or Obese Adult Subjects

Recruiting Phase 1
View on ClinicalTrials.gov →
Record status
This record was last updated September 19, 2025 (before its estimated January 12, 2026 completion). Its status may not reflect the trial's current state.
Summary
This is a Phase 1, single-center, randomized, placebo-controlled, ascending dose study. The study will evaluate the pharmacokinetics (PK), pharmacodynamic (PD), preliminary efficacy, safety and tolerability of BGM0504 following daily oral administrations in non-diabetic overweight or obese adult subjects.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-09-03.
Trial Details
NCT Number NCT07166081
Lead Sponsor BrightGene Bio-Medical Technology Co., Ltd.
Conditions Non-diabetic Overweight or Obese
Enrollment 80 participants
Start Date 2025-08-11
Primary Completion 2026-01-12 (estimated)
Study Completion 2026-05-13 (estimated)
Updated on ClinicalTrials.gov 2025-09-19